Recommended Topic Related To:

Vimpat

"The U.S. Food and Drug Administration today approved a device to help reduce the frequency of seizures in epilepsy patients who have not responded well to medications.

The RNS Stimulator consists of a small neurostimulator implanted within "...

Vimpat

Side Effects
Interactions

SIDE EFFECTS

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

In the premarketing development of adjunctive therapy for partial onset seizures, 1327 patients received VIMPAT in controlled and uncontrolled trials, of whom 1000 were treated for longer than 6 months, and 852 for longer than 12 months. The monotherapy development program included 425 patients, 310 of whom were treated for longer than 6 months, and 254 for longer than 12 months.

VIMPAT Tablet and Oral solution

Monotherapy Historical-Control Trial (Study 1)

In the monotherapy trial, 16% of patients randomized to receive VIMPAT at the recommended doses of 300 and 400 mg/day discontinued from the trial as a result of an adverse event. The adverse reaction most commonly ( ≥ 1% on VIMPAT) leading to discontinuation was dizziness.

Adverse reactions observed in this study were generally similar to those observed and attributed to drug in adjunctive placebo-controlled studies. One adverse reaction, insomnia, was observed at a rate of ≥ 2% and was not reported at a similar rate in previous studies. This adverse reaction has also been observed in postmarketing experience [see ADVERSE REACTIONS]. Because this study did not include a placebo control group, causality could not be established.

Dizziness, headache, nausea, somnolence, and fatigue were all reported at lower incidences during the AED Withdrawal Phase and Monotherapy Phase, compared with the Titration Phase [see Clinical Studies].

Adjunctive TherapyControlled Trials (Studies2, 3, and 4)

In adjunctive therapy controlled clinical trials, the rate of discontinuation as a result of an adverse event was 8% and 17% in patients randomized to receive VIMPAT at the recommended doses of 200 and 400 mg/day, respectively, 29% at 600 mg/day, and 5% in patients randomized to receive placebo. The adverse events most commonly ( > 1% on VIMPAT and greater than placebo) leading to discontinuation were dizziness, ataxia, vomiting, diplopia, nausea, vertigo, and vision blurred.

Table 2 gives the incidence of treatment-emergent adverse events that occurred in ≥ 2% of adult patients with partial-onset seizures in the VIMPAT total group and for which the incidence was greater than placebo. The majority of adverse events in the VIMPAT patients were reported with a maximum intensity of 'mild' or 'moderate'.

Table 2: Treatment-Emergent Adverse Event Incidence in Adjunctive Therapy Double-Blind, Placebo-Controlled Partial-Onset Seizure Trials (Events ≥ 2% of Patients in VIMPAT Total Group and More Frequent Than in the Placebo Group)

System Organ Class/ Preferred Term Placebo
N=364 %
VIMPAT 200 mg/day
N=270 %
VIMPAT 400 mg/day
N=471 %
VIMPAT 600 mg/day
N=203 %
VIMPAT Total
N=944 %
Ear and labyrinth disorder
  Vertigo 1 5 3 4 4
Eye disorders
  Diplopia 2 6 10 16 11
  Vision blurred 3 2 9 16 8
Gastrointestinal disorders
  Nausea 4 7 11 17 11
  Vomiting 3 6 9 16 9
  Diarrhea 3 3 5 4 4
General disorders and administration site conditions
  Fatigue 6 7 7 15 9
  Gait disturbance < 1 < 1 2 4 2
  Asthenia 1 2 2 4 2
Injury, poisoning and procedural complications
  Contusion 3 3 4 2 3
  Skin laceration 2 2 3 3 3
Nervous system disorders
  Dizziness 8 16 30 53 31
  Headache 9 11 14 12 13
  Ataxia 2 4 7 15 8
  Somnolence 5 5 8 8 7
  Tremor  4 4 6 12 7
  Nystagmus 4 2 5 10 5
  Balance disorder 0 1 5 6 4
  Memory impairment 2 1 2 6 2
Psychiatric disorders
  Depression 1 2 2 2 2
Skin and subcutaneous disorders
  Pruritus 1 3 2 3 2

The overall adverse event rate was similar in male and female patients. Although there were few non-Caucasian patients, no differences in the incidences of adverse events compared to Caucasian patients were observed.

Laboratory Abnormalities

Abnormalities in liver function tests have been observed in controlled trials with VIMPAT in adult patients with partial-onset seizures who were taking 1 to 3 concomitant anti-epileptic drugs. Elevations of ALT to ≥ 3 ULN occurred in 0.7% (7/935) of VIMPAT patients and 0% (0/356) of placebo patients. One case of hepatitis with transaminases > 20x ULN was observed in one healthy subject 10 days after VIMPAT treatment completion, along with nephritis (proteinuria and urine casts). Serologic studies were negative for viral hepatitis. Transaminases returned to normal within one month without specific treatment. At the time of this event, bilirubin was normal. The hepatitis/nephritis was interpreted as a delayed hypersensitivity reaction to VIMPAT.

Other Adverse Reactions

The following is a list of treatment-emergent adverse reactions reported by patients treated with VIMPAT in all clinical trials in patients with partial-onset seizures, including controlled trials and long-term open-label extension trials. Events addressed in other tables or sections are not listed here. Events included in this list from the controlled trials occurred more frequently on drug than on placebo and were based on consideration of VIMPAT pharmacology, frequency above that expected in the population, seriousness, and likelihood of a relationship to VIMPAT. Events are further classified within system organ class.

Blood and lymphatic system disorders: neutropenia, anemia

Cardiac disorders: palpitations

Ear and labyrinth disorders: tinnitus

Gastrointestinal disorders: constipation, dyspepsia, dry mouth, oral hypoaesthesia

General disorders and administration site conditions: irritability, pyrexia, feeling drunk

Injury, poisoning, and procedural complications: fall

Musculoskeletal and connective tissue disorders: muscle spasms

Nervous system disorders: paresthesia, cognitive disorder, hypoaesthesia, dysarthria, disturbance in attention, cerebellar syndrome

Psychiatric disorders: confusional state, mood altered, depressed mood

VIMPAT Injection

Adverse reactions with intravenous administration generally were similar to those observed with the oral formulation, although intravenous administration was associated with local adverse events such as injection site pain or discomfort (2.5%), irritation (1%), and erythema (0.5%). One case of profound bradycardia (26 bpm: BP 100/60 mmHg) was observed in a patient during a 15-minute infusion of 150 mg VIMPAT. This patient was on a beta-blocker. Infusion was discontinued and the patient experienced a rapid recovery.

The safety of a 15-minute loading dose administration of VIMPAT Injection 200 mg to 400 mg followed by oral administration of VIMPAT given twice daily at the same total daily dose as the initial intravenous infusion was assessed in an open-label study in patients with partial onset seizures. Patients had to have been maintained on a stable dose regimen of 1 to 2 marketed antiepileptics for at least 28 days prior to treatment assignment. Treatment groups were as follows:

  • Single dose of intravenous VIMPAT Injection 200 mg followed by oral VIMPAT 200 mg/day (100 mg every 12 hours)
  • Single dose of intravenous VIMPAT Injection 300 mg followed by oral VIMPAT 300 mg/day (150 mg every 12 hours)
  • Single dose of intravenous VIMPAT Injection 400 mg followed by oral VIMPAT 400 mg/day (200 mg every 12 hours).
  • Table 3 gives the incidence of adverse events that occurred in ≥ 5% of adult patients in any VIMPAT dosing group.

Table 3: Incidence of Treatment-Emergent Adverse Events in 15-minute infusion study (Events ≥ 5% of subjects in any VIMPAT dose group)

System Organ Class/Preferred term VIMPAT 200 mg
N=25 %
VIMPAT 300 mg
n=50 %
VIMPAT 400 mg
n=25 %
VIMPAT Total
n=100 %
Eye disorders
  Diplopia 4 6 20 9
  Vision blurred 0 4 12 5
Gastrointestinal disorders
  Nausea 0 16 24 14
  Dry mouth 0 6 12 6
  Vomiting 0 4 12 5
  Paraesthesia oral 4 4 8 5
  Hypoaesthesia oral 0 6 8 5
  Diarrhoea 0 8 0 4
General disorders/administration site conditions
  Fatigue 0 18 12 12
  Gait disturbance 8 2 0 3
  Chest pain 0 0 12 3
Nervous system disorders
  Dizziness 20 46 60 43
  Somnolence 0 34 36 26
  Headache 8 4 16 8
  Paraesthesia 8 6 4 6
  Tremor 0 6 4 4
  Coordination abnormal 0 6 0 3
Skin & subcutaneous tissue disorders
  Pruritus 0 6 4 4
  Hyperhidrosis 0 0 8 2

Adverse events observed with infusion of VIMPAT 200 mg over 15-minutes followed by VIMPAT 100 mg administered orally twice day were similar in frequency to those observed in 3-month adjunctive therapy controlled trials. Considering the difference in period of observations (1 week vs. 3 months), the incidence of CNS adverse reactions, such as dizziness, somnolence, and paresthesia may be higher with 15-minute administration of VIMPAT Injection than with administration over a 30-to 60minute period.

Postmarketing Experience

The following adverse reactions have been identified during post-approval use of VIMPAT. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Blood and lymphatic system disorders: Agranulocytosis

Psychiatric disorders: Aggression, agitation, hallucination, insomnia, psychotic disorder

Skin and subcutaneous tissue disorders: Angioedema, rash, urticaria, Stevens-Johnson syndrome, toxic epidermal necrolysis.

Read the Vimpat (lacosamide tablet and injection) Side Effects Center for a complete guide to possible side effects

DRUG INTERACTIONS

Pharmacokinetic Interactions

Drug-drug interaction studies in healthy subjects showed no pharmacokinetic interactions between VIMPAT and carbamazepine, valproate, digoxin, metformin, omeprazole, midazolam, oral contraceptives containing ethinylestradiol and levonorgestrel, or warfarin. There was no evidence for any relevant drug-drug interaction of VIMPAT with the AEDs used most commonly in the placebo-controlled clinical trials in patients with partial-onset seizures [see CLINICAL PHARMACOLOGY]. The lack of pharmacokinetic interaction does not rule out the possibility of pharmacodynamic interactions, particularly among drugs that affect the heart conduction system.

Strong CYP3A4 Or CYP2C9 Inhibitors

Patients with renal or hepatic impairment who are taking strong inhibitors of CYP3A4 and CYP2C9 may have a significant increase in exposure to VIMPAT. Dose reduction may be necessary in these patients.

Concomitant Medications That Prolong PR Interval

VIMPAT should be used with caution in patients on concomitant medications that prolong PR interval, because of a risk of AV block or bradycardia, e.g., beta-blockers and calcium channel blockers. In such patients, obtaining an ECG before beginning VIMPAT, and after VIMPAT is titrated to steady-state, is recommended. In addition, these patients should be closely monitored if they are administered VIMPAT through the intravenous route [see WARNINGS AND PRECAUTIONS].

Drug Abuse And Dependence

Controlled Substance

VIMPAT is a Schedule V controlled substance.

Abuse

In a human abuse potential study, single doses of 200 mg and 800 mg lacosamide produced euphoria-type subjective responses that differentiated statistically from placebo; at 800 mg, these euphoria-type responses were statistically indistinguishable from those produced by alprazolam, a Schedule IV drug. The duration of the euphoria-type responses following lacosamide was less than that following alprazolam. A high rate of euphoria was also reported as an adverse event in the human abuse potential study following single doses of 800 mg lacosamide (15% [5/34]) compared to placebo (0%) and in two pharmacokinetic studies following single and multiple doses of 300-800 mg lacosamide (ranging from 6% [2/33] to 25% [3/12]) compared to placebo (0%). However, the rate of euphoria reported as an adverse event in the VIMPAT development program at therapeutic doses was less than 1%.

Dependence

Abrupt termination of lacosamide in clinical trials with diabetic neuropathic pain patients produced no signs or symptoms that are associated with a withdrawal syndrome indicative of physical dependence. However, psychological dependence cannot be excluded due to the ability of lacosamide to produce euphoria-type adverse events in humans.

Read the Vimpat Drug Interactions Center for a complete guide to possible interactions

Last reviewed on RxList: 9/10/2014
This monograph has been modified to include the generic and brand name in many instances.

Side Effects
Interactions
A A A

Vimpat - User Reviews

Vimpat User Reviews

Now you can gain knowledge and insight about a drug treatment with Patient Discussions.

Here is a collection of user reviews for the medication Vimpat sorted by most helpful. Patient Discussions FAQs

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Epilepsy

Find tips and treatments to control seizures.


NIH talks about Ebola on WebMD